PEDIATRICS Vol. 77 No. 4 April 1986, pp. 551-552
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MOFENSON, H. C.
Right arrow Articles by CARACCIO, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MOFENSON, H. C.
Right arrow Articles by CARACCIO, T. R.

Benefits/Risks of Syrup of Ipecac

HOWARD C. MOFENSON MD1 and THOMAS R. CARACCIO PHARM D1

1 Long Island Regional Poison Control Center, Long Island, NY

The status of syrup of ipecac as a nonprescription drug has helped reduce the death rate in children, ages 1 to 5 years. The drug has proven safe and effective in children in the recommended doses. To deprive parents of ready access to ipecac syrup would result in increased disability and death from poisoning and more emergency department visits.




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
N. R. Kelly and S. H. Sanchez
Is Syrup of Ipecac Still for Sale? Comparison of Pharmacies in a Large Urban Area--2003 Versus 2005
Clinical Pediatrics, May 1, 2007; 46(4): 320 - 324.
[Abstract] [PDF]